- CAR T|Cell Therapy and Secondary T|Cell Cancer Risk🔍
- Second primary malignancies after commercial CAR T|cell therapy🔍
- Risk of secondary cancers after CAR|T cell therapy low🔍
- Risk of Second Tumors and T|Cell Lymphoma after CAR T|Cell ...🔍
- T|cell Malignancies Represent Small Fraction of the Reported ...🔍
- Risk of Secondary Cancers After CAR T Therapy May Be Similar to ...🔍
- Second Primary Malignancies after CAR T|Cell Therapy🔍
- Subsequent Malignancies After CD19|Targeted Chimeric Antigen ...🔍
Secondary Malignancies After CAR T
CAR T-Cell Therapy and Secondary T-Cell Cancer Risk - NCI
One was a study of more than 700 people treated with CAR T-cell therapy at a single cancer center. Over a 9-year period, 25 second cancers were ...
Second primary malignancies after commercial CAR T-cell therapy
Genetic sequencing was performed for 3 cases with the CAR transgene identified in the malignant clones. ... We identified 19 cases of T-cell malignancies (17 T- ...
Risk of secondary cancers after CAR-T cell therapy low, according to ...
... cancer diagnosis. The study's findings suggest that secondary cancers arising after CAR-T cell therapy may be due to baseline ...
Risk of Second Tumors and T-Cell Lymphoma after CAR T-Cell ...
Given the known increased baseline risk of second T-cell malignant tumors in patients with previous B-cell lymphomas even in the absence of CAR ...
T-cell Malignancies Represent Small Fraction of the Reported ...
T-cell Malignancies Represent Small Fraction of the Reported Secondary Cancers following CAR-T in the FDA's Adverse Event Reporting System.
Risk of Secondary Cancers After CAR T Therapy May Be Similar to ...
Risk of Secondary Cancers After CAR T Therapy May Be Similar to Risk After Other Cancer Treatments. ... malignancies (SPMs) arising in cancer ...
Second Primary Malignancies after CAR T-Cell Therapy - PubMed
In a distribution analysis of SPM subtypes, hematologic malignancies were the most common entity (37%), followed by solid tumors (27%) and non- ...
Subsequent Malignancies After CD19-Targeted Chimeric Antigen ...
A total of 17 dermatologic malignancies, 12 solid tumors and 10 hematologic malignancies were identified. The cumulative incidence of subsequent malignancy was ...
Unanswered questions following reports of secondary malignancies ...
Diagnoses included cholangiocarcinoma, synovial sarcoma, malignant melanoma, papillary thyroid carcinoma and three myeloid neoplasms. The median ...
Secondary Cancers Following CAR T Cell Therapy Are Rare
Most of the secondary cancers (12 of the 16) were solid tumors, including skin cancer, prostate cancer, and lung cancer. In one patient who ...
Secondary Cancers After CAR T-Cell Therapy - The ASCO Post
In a distribution analysis of second primary malignancy subtypes, hematologic malignancies were the most common (37%), followed by solid tumors ...
Development of Secondary T-Cell Cancers After the Use of CAR T-Ce
Development of Secondary T-Cell Cancers After the Use of CAR T-Cells for the Treatment of Relapsed or Refractory Haematologic Malignancies.
Long-term outcomes following CAR T cell therapy - Nature
In our long-term follow-up study involving 43 patients with B cell malignancies who received CD19-targeted CAR T cells at the National Cancer ...
Secondary Cancers after Chimeric Antigen Receptor T-Cell Therapy
For now, secondary T-cell cancers occurring after the use of CAR T cells for ... Data mining for second malignancies after CAR-T, Blood, 143, 20, (2023 ...
Second Primary Malignancies after CAR T-Cell Therapy
SPMs were classified into one of the following groups: hematological malignancies, solid tumors, non-melanoma skin cancers, and unknown.
Data mining for second malignancies after CAR-T - ASH Publications
For example, a T-cell malignancy may be more likely to be reported to the FDA after CAR therapy than other types of cancer. In conclusion, ...
Characterization of second primary malignancies post CAR T-cell ...
We found increased rate of hematological malignancies and solid tumors post CAR-T therapy, with T-cell lymphoma and myelodysplastic syndromes ...
Secondary myeloid malignancy after CAR T cell therapy for non ...
Secondary myeloid malignancy after CAR T cell therapy for non-Hodgkin lymphoma (NHL). ... secondary myeloid malignancies in pt treated with CART ...
Second primary malignancies after commercial CAR T-cell therapy
Myeloid and T-cell neoplasms were disproportionately more frequently reported, warranting f … ... Second primary malignancies after commercial CAR ...
FDA Investigating Serious Risk of T-cell Malignancy
FDA has received reports of T-cell malignancies, including chimeric antigen receptor CAR ... secondary malignancies occurring after treatment.